2024
Navigating specific targets of breast cancer symptoms: An innovative computer-simulated intervention analysis
Liang M, Pan Y, Cai J, Xiong Y, Liu Y, Chen L, Xu M, Zhu S, Mei X, Zhong T, Knobf M, Ye Z. Navigating specific targets of breast cancer symptoms: An innovative computer-simulated intervention analysis. European Journal Of Oncology Nursing 2024, 74: 102708. PMID: 39631144, DOI: 10.1016/j.ejon.2024.102708.Peer-Reviewed Original ResearchBreast cancer symptomsBreast cancerMD Anderson Symptom InventoryCross-sectional surveySymptoms of distressCancer symptomsPreventive careSymptom impactSymptom InventoryActivity levelsOptimal interventionSymptom interactionsInterventionDisturbed sleepDistressBreastFatigueCancerSymptomsCareIntervention analysisParticipantsSurveyShort-SleepSentinel and networked symptoms in patients with breast cancer undergoing chemotherapy
Liang M, Zhong T, Knobf M, Chen L, Xu M, Cheng B, Pan Y, Zhou J, Ye Z. Sentinel and networked symptoms in patients with breast cancer undergoing chemotherapy. European Journal Of Oncology Nursing 2024, 70: 102566. PMID: 38513452, DOI: 10.1016/j.ejon.2024.102566.Peer-Reviewed Original ResearchBreast cancer receiving chemotherapyCancer receiving chemotherapyLack of appetiteSymptom clustersSentinel symptomCommunity levelBreast cancerGastrointestinal symptom clusterMD Anderson Symptom InventoryCross-sectional surveyDisturbed sleepBridge symptomsTargeting fatigueExploratory factor analysisSymptom InventoryFactor analysisBreastSymptomsFatigueDiverse symptomsPatientsCommunityCancerSleepDistress
2020
AML-205: Health-Related Quality of Life in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Receiving Glasdegib + Azacitidine
Wang E, Bell T, Zeidan A, Bhattcharyya H, Kudla A, Chan G, Sekeres M. AML-205: Health-Related Quality of Life in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Receiving Glasdegib + Azacitidine. Clinical Lymphoma Myeloma & Leukemia 2020, 20: s191. DOI: 10.1016/s2152-2650(20)30732-1.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeAcute myeloid leukemiaChronic myelomonocytic leukemiaPatient Global ImpressionMyelodysplastic syndromeIntensive chemotherapyPatient's impressionGlobal ImpressionAML cohortMDS cohortMyeloid leukemiaAML/myelodysplastic syndromeMD Anderson Symptom InventoryFirst-line treatment optionLower symptom burdenHRQoL of patientsOpen-label studyHealth-related qualityPatient-reported outcomesEnd of treatmentMain outcome measuresTotal symptom severityQuality of lifeTrend of improvementStudy medicationHealth-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib + azacitidine (AZA).
Wang E, Bell T, Zeidan A, Bhattacharyya H, Kudla A, Chan G, Sekeres M. Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib + azacitidine (AZA). Journal Of Clinical Oncology 2020, 38: 7527-7527. DOI: 10.1200/jco.2020.38.15_suppl.7527.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaAcute myeloid leukemiaMyelodysplastic syndromeIntensive chemotherapyGlobal ImpressionAML cohortAML/myelodysplastic syndromeHigh-risk myelodysplastic syndromeMD Anderson Symptom InventoryFirst-line treatment optionLower symptom burdenPhase Ib studyEnd of treatmentQuality of lifeStudy medicationRemission rateOverall survivalSymptom burdenMDS cohortTreatment optionsMyeloid leukemiaMedian numberMyelomonocytic leukemiaGlasdegibAzacitidine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply